{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:46:18Z","timestamp":1785005178767,"version":"3.55.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2018,12,18]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              is associated with an increased risk for atherosclerotic cardiovascular disease, which may result in many people living with\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              taking a statin. Some statins are contraindicated with certain antiretroviral therapies (\n              <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n              ) and other medications commonly used by\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              \u2010infected patients.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              We analyzed trends in the use of statins, including contraindicated statins, between 2007 and 2015 among\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              \u2010infected patients aged \u226519\u00a0years taking\n              <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n              who had employer\u2010sponsored or Medicare supplemental health insurance in the Marketscan database (n=186\u00a0420). Statin use was identified using pharmacy claims. Contraindicated statin use was defined by a pharmacy claim for\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              protease inhibitors, cobicistat, hepatitis C protease inhibitors, anti\u2010infectives, calcium channel blockers, amiodarone, gemfibrozil, or nefazodone followed by a fill for a contraindicated statin type and dosage within 90\u00a0days. The percentage of beneficiaries with\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              taking a statin remained unchanged between 2007 (24.6%) and 2015 (24.7%). Among those taking a statin, the percentage taking a contraindicated statin declined from 16.3% in 2007 to 9.0% in 2014 and then increased to 9.8% in 2015. The proportion of contraindicated statin fills attributable to\n              <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n              protease inhibitors declined from 63.9% in 2007 to 51.0% in 2015, while those attributable to cobicistat increased from 0% before 2012 to 20.6% in 2015.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Changes in\n              <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n              regimens resulted in a decline in contraindicated statin use from 2007 to 2014, but this favorable trend was attenuated in 2015 because of increased use of cobicistat\u2010containing\n              <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n              regimens.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.118.010345","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T10:01:03Z","timestamp":1544176863000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV\u2010\u2010Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015"],"prefix":"10.1161","volume":"7","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisandro D.","family":"Colantonio","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greer A.","family":"Burkholder","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu261"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(16)30020-2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.063"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.979"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0222-7"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000456"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001708"},{"key":"e_1_3_2_12_2","volume-title":"Panel\u00a0on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV","year":"2017","unstructured":"Panel\u00a0on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV. Washington, DC: Department of Health and Human Services; 2017. Available at: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed February 28, 2018."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0519-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0891-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0145"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.08.002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0075-4"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0160-x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000425824.44694.e8"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1197\/jamia.M2667"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.12.1409"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.256"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh013"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.016"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1205-268"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_2_30_2","volume-title":"FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury","author":"US Food and Drug Administration","year":"2011","unstructured":"US Food and Drug Administration . FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury. Silver Springs, MD: US Department of Health & Human Services; 2011. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm. Accessed April 11, 2016."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4484"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.3384"},{"key":"e_1_3_2_33_2","volume-title":"HIV Surveillance Report, 2016; Vol. 28","author":"Centers for Disease Control Prevention","year":"2017","unstructured":"Centers for Disease Control Prevention . HIV Surveillance Report, 2016; Vol. 28. Atlanta, GA: Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017. Available at: http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html. Accessed February 28, 2018."}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.118.010345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:40:45Z","timestamp":1715600445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.118.010345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,18]]}},"alternative-id":["10.1161\/JAHA.118.010345"],"URL":"https:\/\/doi.org\/10.1161\/jaha.118.010345","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"2018-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e010345"}}